BDNF and major depressive disorder: Moreover, the data also indicate that the effects of both fluoxetine and ketamine in the FST, both used in clinical practice, are mediated via BDNF/TrkB signaling, which could have implications for novel therapies in MDD.<h4>Conclusions</h4>Trk-PAMs could provide an interesting avenue for the development of novel therapeutics in this area.